Archives
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Indeed our immunohistochemical analysis of skin tissue sampl
2021-11-01

Indeed, our immunohistochemical analysis of skin tissue samples without any pathology confirmed the expression of MR and GR. Extending earlier findings in rats (Shaqura et al., 2016a, Shaqura et al., 2016b), we demonstrate here that MR mainly colocalize with the nociceptive neuronal marker CGRP sugg
-
The results obtained here in int Gr and int Gr
2021-11-01

The results obtained here in int-Gr+/+ and int-Gr−/− mice suggested that Gr is required to maintain basal level of Fgf15 expression in the ileum, whereas DEX treatment is able to reduce Fgf15 mRNA in a Gr-independent manner. In previous in vitro studies we have already shown that GC are able to affe
-
Recently some researchers working in
2021-11-01

Recently, some researchers working in China Pharmaceutical University developed novel FFA1 agonists some of which were found to be efficacious in the management of type 2 diabetes and with low toxicity. For instance, Zheng et al. [48] in their in vivo study using experimental animals, reported that
-
Macrophage populations are prominent in active IBD
2021-11-01

Macrophage populations are prominent in active IBD (Strober and James, 1986) as compared to healthy donors. Further, percentages of macrophages are increased in DSS-induced colitis (Grose et al., 2001, Ogawa et al., 2004). IBD is also linked to an influx of neutrophils and depletion of neutrophils b
-
DZNep is a PRC inhibitor that inhibits
2021-11-01

DZNep is a PRC2 inhibitor that inhibits S-adenosylhomocysteine hydrolase, resulting in cellular accumulation of S-adenosylhomocysteine. S-adenosylhomocysteine is a competitive inhibitor of methyl donor for methyltransferases [38]. DZNep targets EZH2 by reduction in the level of the enzyme H3K27me3 a
-
In non Hodgkin lymphoma the
2021-11-01

In non-Hodgkin lymphoma the catalytic SET domain of the histone methyltransferase EZH2 is subject to recurrent heterozygous missense mutations . These alterations have been observed in ∼20% of patients with diffuse large B cell lymphoma (DLBCL) and ∼10% of patients with follicular lymphoma (FL). The
-
br Results and discussion Computer modelling studies suggest
2021-11-01

Results and discussion Computer modelling studies suggested that the endocyclic oxygens in furocoumarin derivatives, such as Go 6983 3a (Fig. 1), could also coordinate metal ions in the HIV-1 IN enzyme active site and inhibit the integration of viral DNA. The coumarin moiety is found in various m
-
br Expression and Purification of
2021-11-01

Expression and Purification of LSD1 Proteins In Vitro Enzymatic Assays Analysis of LSD1 Demethylase Activity Acknowledgments Conflict of Interest Statement: Y.S. is a cofounder of Constellation Pharmaceuticals, Inc. and is a member of its scientific advisory board. Y.S. is also a consu
-
The top panel of Fig depicts the average number
2021-11-01

The top panel of Fig. 3 depicts the average number of planaria visible during each observation for all cohorts in the group testing following light exposure. Although there was considerably more variability than in the light-exposure conditions, a t-test showed no significant difference in count bet
-
CGP 41251 receptor A revolution in cancer immunotherapy has
2021-11-01

A revolution in cancer immunotherapy has recently emerged with the development of novel immunomodulatory antibodies, classified as immunostimulatory agonist monoclonal CGP 41251 receptor (mAbs) or checkpoint blocking mAbs. CD40/CD40L, as an important costimulatory pathway, mediates a broad spectrum
-
br Discussion By using ultra deep sequencing
2021-11-01

Discussion By using ultra-deep sequencing, we conducted a thorough assessment of HCV-NS3 protease variants in chronic PI-naïve patients infected with HCV-1a and HCV-1b under telaprevir-based triple therapy at baseline and after 4weeks of treatment. Several synonymous and non-synonymous substituti
-
In the course of studies leading to the discovery
2021-11-01

In the course of studies leading to the discovery of , modifications at the P3-P4 interface of these tripeptide-based inhibitors were examined with the goal of improving potency while maintaining a PK profile similar to . In this report, we summarize those studies which led to the identification of
-
The neotropical fish Prochilodus lineatus has been widely us
2021-10-29

The neotropical fish Prochilodus lineatus has been widely used in experimental designs for being sensitive to variations in water quality and tolerant to laboratory conditions (Camargo and Martinez, 2006, Cazenave et al., 2014, da Silva and Martinez, 2014, Vieira et al., 2016). Concern and reports a
-
GPR and TRPV co localized in small and
2021-10-29

GPR35 and TRPV1 co-localized in small- and medium-diameter DRG neurons. Nociceptive (Aδ- and C-fiber) neurons expressing TRPV1 mediate hyperalgesia, neurogenic inflammation, and neuropathic pain [12]. The cAMP-protein kinase A (PKA) dependent modifications of TRPV1 currents have been demonstrated in
-
The rat model was validated with another agonist of
2021-10-29

The rat model was validated with another agonist of GPR109A, acipimox. Acipimox has been shown to induce vasodilatation in man, by a mechanism dependent on the release of vasodilator prostaglandins (Edlund et al., 1990, Pontiroli et al., 1992). Acipimox is a weaker agonist of the GPR109A receptor (L
16556 records 588/1104 page Previous Next First page 上5页 586587588589590 下5页 Last page